Dana Farber Cancer Institute, Inc.;達納-法伯癌症研究所股份有限公司
发明人:
GRAY, Nathanael S.,ZHANG, Tinghu,KWIATKOWSKI, Nicholas Paul,T．張,KWIATKOWSKI, Nicholas Paul,N．P．奎亞蒂科夫斯基
申请号：
HK18106030.9
公开号：
HK1246645A
申请日:
2018.05.09
申请国别(地区):
HK
年份:
2018
代理人:
摘要：
The present invention provides novel compounds of Formula (I), (II), or (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., CDK7, CDK12, or CDK13), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.
